. Overview Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural c...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-118532 | EDGAR | 96K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-040771 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034868 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009046 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001193125-25-261696 | EDGAR | 55K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108906 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071996 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124602 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097073 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059099 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060354 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041605 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020836 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000950170-22-020701 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017222 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0000950170-22-009807 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001193125-26-118525 | EDGAR | 4K words |
| 2026-02-06 | 0001193125-26-041169 | EDGAR | — |
| 2025-12-18 | 0001193125-25-323704 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261689 | EDGAR | — |
| 2025-08-14 | 0000950170-25-108898 | EDGAR | — |
| 2025-08-04 | 0000950170-25-101618 | EDGAR | — |
| 2025-07-03 | 0000950170-25-093456 | EDGAR | — |
| 2025-06-18 | 0000950170-25-087907 | EDGAR | — |
| 2025-05-15 | 0000950170-25-071992 | EDGAR | — |
| 2025-03-24 | 0000950170-25-043491 | EDGAR | — |
81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001782223 |
| Ticker | PYXS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pyxisoncology.com |
| Listed | 2021-10-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report